# Acquired Angioedema with C1 Inhibitor Deficiency: Occurrence, Clinical Features, and Management: A Nationwide Retrospective Study in the Czech Republic Patients

- **DOI:** [10.1159/000512933](https://doi.org/10.1159/000512933)
- **Rating:** Sound (3.6 out of 5)
- **Verdict:** A useful nationwide rare-disease cohort adds Czech epidemiology and management evidence, but its 14-patient observational design limits treatment inference.
- **Framework version:** v5.9
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-09-18
- **Evaluation page:** https://www.nabu.science/paper/10.1159%2F000512933

## Key claims

1. The prevalence of AAE-C1-INH in the Czech Republic is about 1:760,000.
   - Support: Supported
   - Type: Primary finding
   - Basis: transparent national case count and population denominator, with possible underdiagnosis limiting completeness
   - Location: Abstract; Discussion, p. 647
2. This rare condition occurs in approximately 8% of the patients with angioedema with C1 inhibitor deficiency.
   - Support: Supported
   - Type: Secondary
   - Basis: reported national counts directly yield 8%, subject to referral-based ascertainment
   - Location: Abstract; Discussion, p. 647
3. AAE-C1-INH is strongly associated with lymphoproliferative disorders, and treating these conditions may improve the control of angioedema symptoms.
   - Support: Tentative
   - Type: Secondary
   - Basis: association is directionally consistent, but treatment improvement rests on seven uncontrolled heterogeneous cases
   - Location: Abstract; Conclusion, p. 648
4. All patients responded to the acute attack treatment with icatibant and plasma-derived or recombinant C1 inhibitor concentrate.
   - Support: Supported
   - Type: Secondary
   - Basis: all recorded treated cases met the response definition, without controlled comparative evidence
   - Location: Abstract; Results, p. 645; Table 3

## Strengths

- **Nationwide specialist-centre case ascertainment** All four Czech referral centres searched their databases using common inclusion criteria, supporting comprehensive capture of symptomatic treated patients within the national specialist system.
  - Dimension: methodological rigour
  - Location: Materials and Methods, p. 643
- **Inspectable patient-level clinical evidence** Tables 2–4 report diagnostic features, laboratory values, treatments, associated conditions, and response classifications for individual patients rather than only aggregate summaries.
  - Dimension: methodological rigour
  - Location: Tables 2–4, pp. 644–646
- **Direct engagement with comparable cohorts** The Discussion compares prevalence, AAE-to-HAE ratio, diagnostic delay, manifestations, and treatment observations with the closest French, Danish, and Italian cohorts.
  - Dimension: positioning
  - Location: Discussion, pp. 647–648

## Limitations

- **Small uncontrolled treatment evidence base** Treatment observations derive from heterogeneous, concurrent interventions in 14 patients, including only seven lymphoma-treated cases. The article appropriately states that it cannot determine treatment superiority.
  - Dimension: methodological rigour
  - Location: Results, pp. 645–647; Discussion, p. 648
- **Abstract compresses outcome complexity** The 6-of-7 lymphoma-response statement combines biological, complete, and partial responses, including one outcome explicitly affected by tranexamic acid and one case too early for assessment.
  - Dimension: reporting
  - Location: Abstract; Results, p. 647; Table 4
- **Limited cross-setting transportability** The prevalence estimate depends on Czech referral-centre capture, while laboratory methods, insurance coverage, underlying diseases, and concomitant treatments varied. These features constrain direct transfer to other health systems.
  - Dimension: application pathway
  - Location: Materials and Methods, pp. 643–644; Table 1; Discussion, pp. 647–648

## Reliability checks

Caveats (4 of 4 checks).

- **Internal coherence:** Noted. The numerical results are internally consistent overall, including the prevalence calculation and disease-category totals. Two Abstract statements compress denominators or heterogeneous outcomes relative to the Results and Table 4, but they do not directly contradict the reported data.
- **Research conduct:** Noted. Ethics approval, written consent, lack of study funding, and author conflicts are explicitly declared. The disclosed relationships include manufacturers whose angioedema treatments are discussed, making them relevant context without indicating concealment or misconduct.
- **Reference integrity:** Clean. 12 of 12 checkable references verified
  - 15 references in manuscript
  - 3 are books, websites or datasets — counted, but not index-checkable
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-10-17